Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oral Topotecan With Toripalimab for Patients With Endometrial Cancer
Sponsor: Fudan University
Summary
This study aims to explore the safety and efficacy of oral topotecan combined with toripalimab in treating advanced/recurrent endometrial cancer through a single-center, prospective, single-arm, phase II clinical trial. The goal is to explore the first-line treatment options for endometrial cancer patients in the era of immunotherapy, to improve the overall treatment level and prognosis of endometrial cancer.
Official title: Oral Topotecan in Combination With Toripalimab for Patients With Advanced/Recurrent Endometrial Cancer: a Phase II Clinical Study
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-11-30
Completion Date
2026-12-31
Last Updated
2024-08-12
Healthy Volunteers
No
Conditions
Interventions
Topotecan
1.4mg/㎡, orally administered, d1-5
Toripalimab
240mg, intravenous drip, d1, q3w
Locations (1)
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Shanghai, Shanghai Municipality, China